AMAG Pharma (AMG) Gets Positive CHMP Opinion for Ferumoxytol

AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron therapy, for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). In the European Union, ferumoxytol will be marketed as Rienso by AMAG’s partner, Takeda Pharmaceutical Company Limited.

European approval and the subsequent first commercial sale of ferumoxytol in Europe would trigger $30 million in milestone payments to AMAG from Takeda. Additionally, AMAG is entitled to receive tiered, double-digit royalties on sales of ferumoxytol in licensed territories. Upon EU Commission approval, Takeda is planning to launch Rienso in the second half of 2012.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA clears path for Protagenic's PT00114 anxiety drug IND submission
• Zentek wins Canada government HVAC filter contract worth CA$348K
• HCW Biologics (HCWB) files for 1.24M share offering by selling stockholders